Dr. Maisel Goes To Washington: CDRH Advisor, Critic Joins Senior Staff
This article was originally published in The Gray Sheet
CDRH has hired a longtime FDA advisor and sometimes outspoken agency and industry critic to lead efforts to improve the way new science is incorporated into agency policies
You may also be interested in...
Senate Democrats are challenging the notion that removing federal pre-emption protection for PMA-approved devices, solidified last year by the Supreme Court, will stifle innovation
New recommendations from leading heart experts call on physicians, device manufacturers and FDA to do a better job monitoring and managing the safety of pacemaker and implantable defibrillator leads
Debate is surfacing in the medical and regulatory community over when clinical data is needed to approve new implantable cardioverter defibrillator technology